Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
10
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
fda
national top stories
biotech
drugs
san francisco blog main
alnylam pharmaceuticals
avapritinib
blueprint medicines
new york blog main
new york top stories
onpattro
patisiran
san francisco top stories
akcea therapeutics
cancer
deals
eli lilly
european medicines agency
genentech
hereditary transthyretin amyloidosis
inotersen
investing
medullary thyroid cancer
non-small cell lung cancer
pfizer
postpartum depression
pralsetinib
rna interference
roche
sage therapeutics
san diego blog main
san diego top stories
selpercatinib
svb leerink
What
drug
10
×
fda
10
×
medicine
approval
alnylam
approved
blueprint
cancer
medicines
rnai
therapeutics
approves
depression
filing
hits
interference
new
pharmaceuticals
phase
plans
ret
rna
seek
specifically
type
address
affects
afternoon
ago
aldeyra
alnylam’s
americans
announced
brexanalone
brexanolone
candidate
carries
cells
certain
chasing
Language
unset
Current search:
boston
×
fda
×
drug
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug